Red Blood Cells and Tranexamic Acid in the Inhibition of Fibrinolysis
Seminars in Thrombosis and Hemostasis · 01.07.2026 · 52 (05) · 593-600
DOI: 10.1055/a-2609-3677 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Thrombosis and Hemostasis, erschienen am 01.07.2026. Verfasst von Nikolett Wohner und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Semmelweis University, Budapest, Hungary. Hauptthemen laut MEDLINE: Tranexamic Acid, Fibrinolysis, Erythrocytes, Antifibrinolytic Agents. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hungarian National Research, Development and Innovation Office (NKFIH), Thematic Institutional Excellence funding scheme of the Ministry of Innovation and Technology in Hungary, Central Europe Leuven Strategic Alliance CELSA research fund.
Abstract (Originalsprache)
Tranexamic acid (TXA) is a widely used and cost-effective antifibrinolytic agent that has been utilized for decades in various clinical situations involving bleeding complications. Over time, a growing amount of clinical evidence has emerged, offering a robust basis for its applications. However, in certain clinical scenarios, TXA appears to be less effective, highlighting the need for further research into its mechanisms of action beyond its well-known antifibrinolytic effects. One area of particular interest is the interaction between TXA and blood cells, especially red blood cells (RBCs). This interaction has garnered significant attention due to intriguing findings from large clinical trials, such as the WOMAN-1 and -2 studies, which evaluated the efficacy of TXA in preventing bleeding in postpartum hemorrhage, a major childbirth complication. These trials revealed that TXA was less effective in anemic patients, raising important questions about its broader mechanisms of action. Emerging evidence suggests that the relationship between TXA and blood cells plays a crucial role at various stages of hemostasis, expanding its established role in fibrinolysis inhibition. Recent investigations into the interactions between TXA and RBCs have been particularly compelling and may provide valuable insights for improving clinical outcomes. This review provides a fresh look at the interplay between RBCs, TXA, and the hemostatic system, focusing on basic molecular mechanisms and their potential implications for clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, Semmelweis University, Budapest, Hungary.
- Department of Biochemistry, HCEMM-SU Thrombosis and Hemostasis Research Group, Semmelweis University, Budapest, Hungary.
ORCID-Profile: Nikolett Wohner
Förderung
- Hungarian National Research, Development and Innovation Office (NKFIH)
- Thematic Institutional Excellence funding scheme of the Ministry of Innovation and Technology in Hungary
- Central Europe Leuven Strategic Alliance CELSA research fund
Zitieren
APA
Wohner, N., Balog Virag, K., Raska, A., & Kolev, K. (2026). Red Blood Cells and Tranexamic Acid in the Inhibition of Fibrinolysis. Seminars in Thrombosis and Hemostasis, 52(05), 593-600. https://doi.org/10.1055/a-2609-3677
Vancouver
Wohner N, Balog Virag K, Raska A, Kolev K. Red Blood Cells and Tranexamic Acid in the Inhibition of Fibrinolysis. Seminars in Thrombosis and Hemostasis. 2026;52(05):593-600. doi:10.1055/a-2609-3677
BibTeX
@article{Wohner2026,
author = {Wohner, Nikolett and Balog Virag, Kata and Raska, Alexandra and Kolev, Krasimir},
title = {Red Blood Cells and Tranexamic Acid in the Inhibition of Fibrinolysis},
journal = {Seminars in Thrombosis and Hemostasis},
year = {2026},
volume = {52},
number = {05},
pages = {593--600},
doi = {10.1055/a-2609-3677}
}
EUVIMED